Artivion, Inc. · NYSE:AORT
Artivion — Q2 2026 Earnings Presentation
22 slides from Artivion's earnings presentation, Aug 6, 2026
Slide 1: 2Q 2026 Earnings Presentation
2Q 2026 Earnings Presentation August 6, 2026 1 © 2026 Artivion, Inc.
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management’s beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect
Slide 3: Non-GAAP Financial Measures
NON-GAAP FINANCIAL MEASURES This presentation contains non-GAAP financial measures, including non-GAAP adjusted revenue, non-GAAP net income, EBITDA, adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in
Slide 4: Table of Contents
TABLE OF CONTENTS Key Messages 5 Q2 2026 Financial Highlights 6 Product Revenue Growth 7 Geographic Revenue Growth 8 On-X vs Bioprosthetic Valve Data & Market Opportunity 9-10 U.S. Complex Aortic Arch Market Portfolio 11-14 Full Year 2026 Financial Guidance 15-16 Appendix 17-21 4 © 2026 Artivion, In
Slide 5: Q2 Key Messages
Q2 Key Messages Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis PMA obviates lengthy IRB process associated with sales under Humanitarian Device Exemption AMDS set-sales improved relative to 1Q26 $125.8M Completed Acquisition of Endospan Following U.S. FDA PMA Approval of $26.4M REVENU
Slide 6: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights GAAP Non-GAAP Q2 2026 Q2 2025 % Y/Y Δ Q2 2026 Q2 2025 % Y/Y Δ Revenue $125.8M $113.0M 11.3% Revenue $125.8M $115.3M 9.1% Gross Gross 64.0% 64.7% (70 bps) 64.0% 64.7% (70 bps) Margin Margin Diluted EPS ($0.28) $0.03 -- Diluted EPS $0.13 $0.24 -- Net (loss) Adjusted ($13.5
Slide 7: Q2 2026 Year-Over-Year Revenue Growth
Q2 2026 Year-Over-Year Revenue Growth Product Portfolio Preservation Surgical Aortic Stent On-X Services Sealant Grafts GAAP Growth 1% 0% 19% 16% Constant Currency Growth 1% (2%) 18% 12% 7 © 2026 Artivion, Inc.
Slide 8: Q2 2026 Year-Over-Year Revenue Growth Across Geographies
Q2 2026 Year-Over-Year Revenue Growth Across Geographies North Latin America America EMEA APAC GAAP Growth 8% 21% 15% 9% Constant Currency 8% 11% 10% 9% Growth 8 © 2026 Artivion, Inc.
Slide 9: On-X: Significant Market Opportunity For Profitable, Cash Generating Product Line
On-X: Significant Market Opportunity For Profitable, Cash Generating Product Line Current On-X Remaining Mechanical BPV <65 Market Total Global On-X Business Valve Market Opportunity Expansion Opportunity Market Opportunity ~$150M ~$400M Only mechanical heart valve indicated for Low INR of 1.5– 2.
Slide 10: U.S. Complex Aortic Arch Market Portfolio
U.S. COMPLEX AORTIC ARCH MARKET PORTFOLIO Innovation Leader in Space with Acceptable Reimbursement; New MS-DRG Code 209, effective October 1, 2025 Arcevo LSA NEXUS ONE Pivotal Trial Enrolling PMA Approved; Recently Acquired AMDS NEXUS DUO / TRE PMA Approved PMA Pipeline NEXUS Ascending NEXUS LSA PM
Slide 11: AMDS PERSEVERE US IDE Study Primary Endpoints
AMDSTM PERSEVERE US IDE Study Primary Endpoints Full IDE data demonstrates AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control group ACUTE DEBAKEY TYPE I (ADTI) Through Hospital WITH MALPERFUSION Full 30-Day Discharge Data Data Hemiarch Reference Cohort Avg.
Slide 12: Endospan NEXUS TRIOMPHE US IDE Trial
Endospan NEXUS ® TRIOMPHE US IDE Trial 30-day data demonstrate 63% reduction in major adverse event (MAE) Presented at rate compared to the reference performance goal AATS 2026 30-DAY DATA 1 TRIOMPHE Performance p Value (n=54) Goal MAEs2 >=1 13.0% 35.0% p<0.001 Technical Failure 1.9% 30.0% p<0.001 3
Slide 13: ARTIZEN Pivotal IDE Study
ARTIZEN PIVOTAL IDE Study Prospective, Non-randomized, Non-blinded, Double-arm, Multicenter (US & EU ≈ 30 Sites) PRIMARY PATIENT GROUP • 117 patients: Chronic dissection or Aneurysm • Primary endpoint: Freedom from major adverse events (MAEs) within 1-year post-index procedure: all-cause mortality,
Slide 14: New Long-Term Study Shows Excellent Survival & Durability with the Ross Procedure
New Long-Term Study Shows Excellent Survival & Durability with the Ross Procedure Published in JACC: Journal of The American College of Cardiology in June 2026 STUDY DESIGN • 455 consecutive adult Ross procedures at a single high-volume Ross center from Actuarial Survival After the 2011–2019; 95% (n
Slide 15: Full Year 2026 Revenue Guidance
Full Year 2026 Revenue Guidance GROWTH DRIVERS + Continued strength in existing products On-X and aortic stents $90.0M + Positive new data supporting the benefits of AMDS and On-X aortic valves $480M- Revenue* ($) $443.6M $496M + Continued adoption of AMDS following Y/Y cc. 13% 7-11% receipt FDA PMA
Slide 16: Revenue Growth & Operating Leverage to Drive Adjusted EBITDA Expansion
Revenue Growth & Operating Leverage to Drive Adjusted EBITDA Expansion FULL YEAR 2026 ADJUSTED EBITDA EXPECTATIONS* DRIVERS Expect continued operating leverage to be $90.0M driven by gross margin expansion, global sales force and G&A infrastructure $92M- Adjusted EBITDA ($) $89.6M $99M *Now includes
Slide 17: Appendix
Appendix 17 © 2026 Artivion, Inc.
Slide 18: Q2 2026 GAAP to Non-GAAP Financial Reconciliations
Q2 2026 GAAP to Non-GAAP Financial Reconciliations Revenue $ in thousands © 2026 Artivion, Inc. 18
Slide 19: Q2 2026 GAAP to Non-GAAP Financial Reconciliations
Q2 2026 GAAP to Non-GAAP Financial Reconciliations Reconciliation of diluted (loss) income per common share, GAAP to adjusted diluted income per common share, non-GAAP In thousands, except per share data © 2026 Artivion, Inc. 19
Slide 20: Q2 2026 GAAP to Non-GAAP Financial Reconciliations
Q2 2026 GAAP to Non-GAAP Financial Reconciliations Reconciliation of net (loss) income, GAAP and EBITDA, non-GAAP to adjusted EBITDA, non-GAAP $ in thousands © 2026 Artivion, Inc. 20
Slide 21: Q2 2026 GAAP to Non-GAAP Financial Reconciliations
Q2 2026 GAAP to Non-GAAP Financial Reconciliations Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP $ in thousands © 2026 Artivion, Inc. 21
Slide 22: Thank You
Thank You © 2026 Artivion, Inc.